Surzebiclimab

DB16669InvestigationalProtein Based Therapies

Surzebiclimab is under investigation in clinical trial NCT03744468 (Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors).

Mechanism: Pharmacologically active on Hepatitis A virus cellular receptor 2
Curator reviewed
Code names: Anti-TIM-3 monoclonal antibody BGB-A425 · BGB-A425

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Surzebiclimab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.